201 related articles for article (PubMed ID: 19159919)
1. Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats.
Marin C; Aguilar E; Rodríguez-Oroz MC; Bartoszyk GD; Obeso JA
Psychopharmacology (Berl); 2009 Jun; 204(2):241-50. PubMed ID: 19159919
[TBL] [Abstract][Full Text] [Related]
2. Role of dopamine D3 and serotonin 5-HT 1A receptors in L: -DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Gerlach M; Bartoszyk GD; Riederer P; Dean O; van den Buuse M
J Neural Transm (Vienna); 2011 Dec; 118(12):1733-42. PubMed ID: 21253782
[TBL] [Abstract][Full Text] [Related]
3. Subthalamic 6-OHDA-induced lesion attenuates levodopa-induced dyskinesias in the rat model of Parkinson's disease.
Marin C; Bonastre M; Mengod G; Cortés R; Rodríguez-Oroz MC; Obeso JA
Exp Neurol; 2013 Dec; 250():304-12. PubMed ID: 24140562
[TBL] [Abstract][Full Text] [Related]
4. Buspirone requires the intact nigrostriatal pathway to reduce the activity of the subthalamic nucleus via 5-HT1A receptors.
Sagarduy A; Llorente J; Miguelez C; Morera-Herreras T; Ruiz-Ortega JA; Ugedo L
Exp Neurol; 2016 Mar; 277():35-45. PubMed ID: 26687972
[TBL] [Abstract][Full Text] [Related]
5. Bilateral subthalamic nucleus lesion reverses L-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats.
Marin C; Jiménez A; Tolosa E; Bonastre M; Bové J
Synapse; 2004 Feb; 51(2):140-50. PubMed ID: 14618681
[TBL] [Abstract][Full Text] [Related]
6. The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy.
Eskow KL; Gupta V; Alam S; Park JY; Bishop C
Pharmacol Biochem Behav; 2007; 87(3):306-14. PubMed ID: 17553556
[TBL] [Abstract][Full Text] [Related]
7. Naloxone reduces levodopa-induced dyskinesias and apomorphine-induced rotations in primate models of parkinsonism.
Klintenberg R; Svenningsson P; Gunne L; Andrén PE
J Neural Transm (Vienna); 2002 Oct; 109(10):1295-307. PubMed ID: 12373562
[TBL] [Abstract][Full Text] [Related]
8. L-DOPA-induced dyskinesia in adult rats with a unilateral 6-OHDA lesion of dopamine neurons is paralleled by increased c-fos gene expression in the subthalamic nucleus.
Soghomonian JJ
Eur J Neurosci; 2006 May; 23(9):2395-403. PubMed ID: 16706847
[TBL] [Abstract][Full Text] [Related]
9. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability.
Iravani MM; Tayarani-Binazir K; Chu WB; Jackson MJ; Jenner P
J Pharmacol Exp Ther; 2006 Dec; 319(3):1225-34. PubMed ID: 16959959
[TBL] [Abstract][Full Text] [Related]
10. The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram.
Kuan WL; Zhao JW; Barker RA
Psychopharmacology (Berl); 2008 Apr; 197(2):279-93. PubMed ID: 18157704
[TBL] [Abstract][Full Text] [Related]
11. High frequency stimulation of the subthalamic nucleus improves treadmill locomotion in unilateral 6-hydroxydopamine lesioned rats.
Chang JY; Shi LH; Luo F; Woodward DJ
Brain Res; 2003 Sep; 983(1-2):174-84. PubMed ID: 12914978
[TBL] [Abstract][Full Text] [Related]
12. The involvement of RGS9 in l-3,4-dihydroxyphenylalanine-induced dyskinesias in unilateral 6-OHDA lesion rat model.
Yin LL; Geng XC; Zhu XZ
Brain Res Bull; 2011 Nov; 86(5-6):367-72. PubMed ID: 21963945
[TBL] [Abstract][Full Text] [Related]
13. The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat.
Dupre KB; Eskow KL; Negron G; Bishop C
Brain Res; 2007 Jul; 1158():135-43. PubMed ID: 17553470
[TBL] [Abstract][Full Text] [Related]
14. (6aR)-11-amino-N-propyl-noraporphine, a new dopamine D2 and serotonin 5-HT1A dual agonist, elicits potent antiparkinsonian action and attenuates levodopa-induced dyskinesia in a 6-OHDA-lesioned rat model of Parkinson's disease.
Zhao R; Lu W; Fang X; Guo L; Yang Z; Ye N; Zhao J; Liu Z; Jia J; Zheng L; Zhao B; Zhang A; Zhen X
Pharmacol Biochem Behav; 2014 Sep; 124():204-10. PubMed ID: 24955866
[TBL] [Abstract][Full Text] [Related]
15. Effects of piclozotan (SUN N4057), a partial serotonin 1A receptor agonist, on motor complications induced by repeated administration of levodopa in parkinsonian rats.
Tani Y; Ogata A; Koyama M; Inoue T
Eur J Pharmacol; 2010 Dec; 649(1-3):218-23. PubMed ID: 20858480
[TBL] [Abstract][Full Text] [Related]
16. Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models.
Bibbiani F; Oh JD; Chase TN
Neurology; 2001 Nov; 57(10):1829-34. PubMed ID: 11723272
[TBL] [Abstract][Full Text] [Related]
17. Effects of oligonucleotide antisense to dopamine D(1A) receptor messenger RNA in a rodent model of levodopa-induced dyskinesia.
Van Kampen JM; Stoessl AJ
Neuroscience; 2000; 98(1):61-7. PubMed ID: 10858612
[TBL] [Abstract][Full Text] [Related]
18. Antidepressant-like properties of sarizotan in experimental Parkinsonism.
Zhang X; Egeland M; Svenningsson P
Psychopharmacology (Berl); 2011 Dec; 218(4):621-34. PubMed ID: 21647579
[TBL] [Abstract][Full Text] [Related]
19. Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on L-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat.
Dupre KB; Eskow KL; Steiniger A; Klioueva A; Negron GE; Lormand L; Park JY; Bishop C
Psychopharmacology (Berl); 2008 Jul; 199(1):99-108. PubMed ID: 18545986
[TBL] [Abstract][Full Text] [Related]
20. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
Grégoire L; Samadi P; Graham J; Bédard PJ; Bartoszyk GD; Di Paolo T
Parkinsonism Relat Disord; 2009 Jul; 15(6):445-52. PubMed ID: 19196540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]